In this discussion, Edmarie Guzman-Velez, a former Harvard researcher and now assistant professor, and Rudy Tanzi, a prominent neurology professor at Harvard, delve into a clinical trial on nicotinamide riboside (NR) for Long Covid symptoms. They explore how NAD+, crucial for cellular energy, may be depleted by COVID, leading to fatigue and cognitive issues. Remarkably, the trial showed a threefold rise in NAD+, with improvements in fatigue, sleep, and mood. Caution is advised on dosing, emphasizing the need for medical oversight.
